Abzena PLC Licence agreement (5797S)
December 22 2016 - 1:00AM
UK Regulatory
TIDMABZA
RNS Number : 5797S
Abzena PLC
22 December 2016
Abzena plc
Licence agreement for Composite Human Antibody(TM)
technology
Cambridge, UK, 22 December 2016 - Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), a life sciences group providing services
and technologies to enable the development and manufacture of
biopharmaceutical products, has signed a licence agreement with
Trieza Therapeutics, Inc ('Trieza'). Trieza is a start-up
biotechnology company specialising in the discovery and development
of immunomodulatory oncolytic viruses based in Cambridge, MA,
USA.
Abzena has granted Trieza an exclusive worldwide, royalty
bearing, sub-licensable licence to an undisclosed antibody
sequence, which was created using the Group's Composite Human
Antibody(TM) technology, for exploitation in conjunction with
Trieza's viral vector technology to develop novel therapies in
oncology.
Abzena could receive up to $35m in development and commercial
milestone payments as well as royalties on the sale of licensed
products containing the Abzena sequence.
Dr John Burt, Abzena's CEO, commented:
"This new licence deal with Trieza provides the opportunity for
Abzena to benefit from the commercialisation of one of the assets
originally developed by the Group to exemplify its proprietary
antibody humanization and deimmunisation technology. Our Abzena
inside portfolio already has eleven products in the clinic that
have benefitted from this technology."
Dr Dan Hicklin, Trieza Therapeutics' CEO, said: "We are pleased
to enter this relationship with Abzena. Access to Abzena's
technology will accelerate the development of Trieza's portfolio of
immunotherapeutic oncolytic virus product candidates".
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
+44 20 7260
Numis (Nominated Adviser and Broker) 1000
Clare Terlouw / James Black / Paul
Gillam
N+1 Singer (Joint Broker) +44 207 496
Aubrey Powell / Liz Yong 3000
Instinctif Partners
Melanie Toyne Sewell / Rozi +44 20 7457
Morris 2020
abzena@instinctif.com
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
About Trieza Therapeutics, Inc
Trieza Therapeutics was formed in Q4 2016 as a spin-out from
Potenza Therapeutics to more fully support certain oncolytic virus
programs initiated at Potenza Therapeutics. The company is financed
by the same investors as Potenza and operates independently of the
Potenza-Astellas strategic partnership which has been ongoing since
April 2015.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRKMMZZVZDGVZG
(END) Dow Jones Newswires
December 22, 2016 02:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024